Increasing evidence for the efficacy of JAK inhibitors in other immune-mediated diseases and murine studies of lupus led to the first RCT of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in SLE (17). The gene discussed is TYK2; the disease is systemic lupus erythematosus.